BioXcel Therapeutics, Inc. Earnings Per Share (Basic)
BioXcel Therapeutics, Inc. (BTAI) reported Earnings Per Share (Basic) of -$0.49 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- BioXcel Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.49.
- BioXcel Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.54.
- BioXcel Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.57.
- BioXcel Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$2.18.
- BioXcel Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$5.73.
- BioXcel Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$23.51.
- BioXcel Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$98.33.
- BioXcel Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$5.92.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.49 10-Q · filed 2026-08-13 | -$1.02 10-Q · filed 2026-08-13 | -$1.58 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.15 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2026-03-31 | -$0.54 10-Q · filed 2026-05-15 | -$1.11 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.83 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$4.47 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-12-31 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$2.41 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$4.28 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$5.73 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | -$2.18 10-Q · filed 2025-11-12 | -$4.55 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$6.38 10-Q · filed 2025-11-12 | -$9.12 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-06-30 | -$2.45 10-Q · filed 2026-08-13 | -$4.17 10-Q · filed 2026-08-13 | -$7.12 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$11.10 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-03-31 | -$1.50 10-Q · filed 2026-05-15 | -$4.60 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$9.05 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$12.29 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2024-12-31 | -$3.57 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$8.61 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$11.99 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$23.51 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | -$5.15 10-Q · filed 2025-11-12 | -$0.32 10-Q · filed 2024-11-14 | -$8.50 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$20.60 10-Q · filed 2025-11-12 | -$1.29 10-Q · filed 2024-11-14 | $3.91 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||
| 2024-06-30 | -$3.30 10-Q · filed 2025-08-12 | -$0.21 10-Q · filed 2024-08-06 | -$15.78 10-Q · filed 2025-08-12 | -$0.99 10-Q · filed 2024-08-06 | $2.28 derived: net income ÷ weighted average shares · filed 2025-11-12 | $9.36 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||
| 2024-03-31 | -$13.89 10-Q · filed 2025-05-12 | -$0.87 10-Q · filed 2024-05-09 | $1.26 derived: net income ÷ weighted average shares · filed 2025-11-12 | $6.14 derived: net income ÷ weighted average shares · filed 2025-11-12 | $31.54 derived: net income ÷ weighted average shares · filed 2025-11-12 | |||
| 2023-12-31 | $0.28 derived: net income ÷ weighted average shares · filed 2025-03-28 | $2.88 derived: net income ÷ weighted average shares · filed 2025-03-28 | $17.75 derived: net income ÷ weighted average shares · filed 2025-03-28 | -$98.33 10-K · filed 2025-03-28 | -$6.15 10-K · filed 2024-03-22 | |||
| 2023-09-30 | -$1.72 10-Q · filed 2024-11-14 | -$3.56 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$5.40 10-Q · filed 2024-11-14 | -$7.35 derived: net income ÷ weighted average shares · filed 2024-11-14 | ||||
| 2023-06-30 | -$1.83 10-Q · filed 2024-08-06 | -$3.68 10-Q · filed 2024-08-06 | -$5.63 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$7.13 derived: net income ÷ weighted average shares · filed 2024-11-14 | ||||
| 2023-03-31 | -$1.84 10-Q · filed 2024-05-09 | -$3.80 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$5.29 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$6.64 derived: net income ÷ weighted average shares · filed 2024-11-14 | ||||
| 2022-12-31 | -$1.95 derived: net income ÷ weighted average shares · filed 2024-03-22 | -$3.44 derived: net income ÷ weighted average shares · filed 2024-03-22 | -$4.79 derived: net income ÷ weighted average shares · filed 2024-03-22 | -$5.92 10-K · filed 2024-03-22 | ||||
| 2022-09-30 | -$1.49 10-Q · filed 2023-11-14 | -$2.84 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$3.96 10-Q · filed 2023-11-14 | -$4.90 derived: net income ÷ weighted average shares · filed 2023-11-14 | ||||
| 2022-06-30 | -$1.35 10-Q · filed 2023-08-14 | -$2.47 10-Q · filed 2023-08-14 | -$3.40 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$4.36 derived: net income ÷ weighted average shares · filed 2023-11-14 | ||||
| 2022-03-31 | -$1.12 10-Q · filed 2023-05-09 | -$2.06 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$3.02 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$4.11 derived: net income ÷ weighted average shares · filed 2023-11-14 | ||||
| 2021-12-31 | -$0.93 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$1.89 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$2.99 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$4.05 10-K · filed 2023-03-16 | ||||
| 2021-09-30 | -$0.96 10-Q · filed 2022-11-14 | -$2.06 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$3.13 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$1.11 10-Q · filed 2022-08-11 | -$2.18 10-Q · filed 2022-08-11 | ||||||
| 2021-03-31 | -$1.08 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | -$3.79 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |